Aileron Price To Operating Cash Flows Ratio from 2010 to 2024

ALRN Stock  USD 2.86  0.12  4.38%   
Aileron Therapeutics Price To Operating Cash Flows Ratio yearly trend continues to be very stable with very little volatility. Price To Operating Cash Flows Ratio is likely to drop to -0.74. During the period from 2010 to 2024, Aileron Therapeutics Price To Operating Cash Flows Ratio quarterly data regression pattern had range of 9.8281 and standard deviation of  3.02. View All Fundamentals
 
Price To Operating Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
(0.71)
Current Value
(0.74)
Quarterly Volatility
3.02104067
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Aileron Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aileron Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 384 K, Selling General Administrative of 10.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.14, Dividend Yield of 0.0 or PTB Ratio of 2.14. Aileron financial statements analysis is a perfect complement when working with Aileron Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aileron Therapeutics Correlation against competitors.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.

Latest Aileron Therapeutics' Price To Operating Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Operating Cash Flows Ratio of Aileron Therapeutics over the last few years. It is Aileron Therapeutics' Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aileron Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price To Operating Cash Flows Ratio10 Years Trend
Very volatile
   Price To Operating Cash Flows Ratio   
       Timeline  

Aileron Price To Operating Cash Flows Ratio Regression Statistics

Arithmetic Mean(1.99)
Coefficient Of Variation(151.73)
Mean Deviation2.12
Median(0.53)
Standard Deviation3.02
Sample Variance9.13
Range9.8281
R-Value0.04
Mean Square Error9.81
R-Squared0
Significance0.88
Slope0.03
Total Sum of Squares127.77

Aileron Price To Operating Cash Flows Ratio History

2024 -0.74
2023 -0.71
2022 -0.43
2021 -2.1
2020 -1.77
2019 -0.53
2018 -0.44

About Aileron Therapeutics Financial Statements

Aileron Therapeutics investors utilize fundamental indicators, such as Price To Operating Cash Flows Ratio, to predict how Aileron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price To Operating Cash Flows Ratio(0.71)(0.74)

Pair Trading with Aileron Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aileron Stock

  0.66EWTX Edgewise TherapeuticsPairCorr
  0.72BHC Bausch Health CompaniesPairCorr

Moving against Aileron Stock

  0.52ELAN Elanco Animal HealthPairCorr
  0.48INAB In8bio IncPairCorr
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aileron Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aileron Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aileron Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aileron Therapeutics Stock:
Check out the analysis of Aileron Therapeutics Correlation against competitors.
To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.88)
Return On Assets
(0.26)
Return On Equity
(0.44)
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.